FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
FDA General

FDA User Fees Bill Voted Out of Senate Committee

The Senate Health, Education, Labor & Pensions Committee votes 21-2 to advance S. 934, the FDA Reauthorization Act of 2017, that would reauthorize FDA...

Medical Devices

NxStage Medical Next Gen Hemodialysis System Cleared

FDA clears a NxStage Medical 510(k) for its next generation hemodialysis system, NxStage System One.

Medical Devices

NDS Gains Clearance for ZeroWire Battery Stand

FDA clears an NDS 510(k) for its new ZeroWire Mobile battery-powered display stand solution, which is intended to enable untethered clinical mobility ...

Human Drugs

FDA Accelerated Approval for Mercks Keytruda in Lung Cancer

FDA grants accelerated approval for Mercks Keytruda (pembrolizumab) in combination with pemetrexed (Alimta) and carboplatin, for first-line treatment ...

Human Drugs

Objectionable Conditions at Clinical Trial Site

FDA warns Indiana University School of Medicines Merrill Benson about objectionable conditions at a clinical trial of an investigation drug for which ...

Human Drugs

Aurobindo FDA-483 Released

FDA releases an FDA-483 with seven observations from an agency inspection at Indias Aurobindo Pharma.

Federal Register

FDA Amends Animal Drug Regs to Reflect Approvals

Federal Register final rule: FDA amends the animal drug regulations to reflect application-related actions for new animal drug applications and abbrev...

Federal Register

FDA Withdrawing Approval of Sioux Bio Animal Drug

Federal Register notice: FDA withdraws approval of a new animal drug application at the sponsors request because the product is no longer manufactured...

Human Drugs

Genentech Reports Disappointing Phase 3 Tecentriq Results

Genentech says its Phase 3 study IMvigor211 that evaluated Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer wh...

Human Drugs

Research Criteria for PhRMA Membership

PhRMA adds research requirements to its membership criteria, dropping companies that dont spend enough on research and development of new therapies.